Tysabri Lowers MS Disability Risk in 2-Year Trial

LOS ANGELES (Reuters) - Biogen Idec and Elan Corp. on Tuesday reported for the first time full results from a pivotal-stage trial of their suspended multiple sclerosis drug Tysabri, showing that it slows disability in relapsed MS patients.

Continue to Tysabri Lowers MS Disability Risk in 2-Year Trial on Reuters: Health.

Medical Buzz delivers the most recent headlines from the medical world. Diseases, cures, accidents, medicin. Click below for more headlines ...
Medical buzz